CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: ZNF611 (ImmuneEditome ID:81856)

1. Gene summary of enriched editing regions for ZNF611

check button Gene summary
Gene informationGene symbol

ZNF611

Gene ID

81856

GeneSynonyms-
GeneCytomap

19q13.41

GeneTypeprotein-coding
GeneDescriptionzinc finger protein 611
GeneModificationdate20230518
UniprotIDQ8N823;M0QYZ5;M0R2W3;A0A1W2PQH1;M0QYR0;M0QXE4;M0QXQ6;M0R1T1
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr19:52703301-52704156:-ENST00000453741.5ENSG00000213020.7ZNF611UTR3AluY,AluSz,AluSxchr19:52703301-52704156:-.alignment
chr19:52703301-52704156:-ENST00000540744.4ENSG00000213020.7ZNF611UTR3AluY,AluSz,AluSxchr19:52703301-52704156:-.alignment
chr19:52703301-52704156:-ENST00000543227.4ENSG00000213020.7ZNF611UTR3AluY,AluSz,AluSxchr19:52703301-52704156:-.alignment
chr19:52703301-52704156:-ENST00000595001.4ENSG00000213020.7ZNF611UTR3AluY,AluSz,AluSxchr19:52703301-52704156:-.alignment
chr19:52703301-52704156:-ENST00000602162.4ENSG00000213020.7ZNF611UTR3AluY,AluSz,AluSxchr19:52703301-52704156:-.alignment
chr19:52709309-52710449:-ENST00000319783.4ENSG00000213020.7ZNF611intronicMLT1A,AluSz,AluSc,AluSpchr19:52709309-52710449:-.alignment
chr19:52709309-52710449:-ENST00000453741.5ENSG00000213020.7ZNF611intronicMLT1A,AluSz,AluSc,AluSpchr19:52709309-52710449:-.alignment
chr19:52709309-52710449:-ENST00000540744.4ENSG00000213020.7ZNF611intronicMLT1A,AluSz,AluSc,AluSpchr19:52709309-52710449:-.alignment
chr19:52709309-52710449:-ENST00000543227.4ENSG00000213020.7ZNF611intronicMLT1A,AluSz,AluSc,AluSpchr19:52709309-52710449:-.alignment
chr19:52709309-52710449:-ENST00000595001.4ENSG00000213020.7ZNF611intronicMLT1A,AluSz,AluSc,AluSpchr19:52709309-52710449:-.alignment
chr19:52709309-52710449:-ENST00000595798.4ENSG00000213020.7ZNF611intronicMLT1A,AluSz,AluSc,AluSpchr19:52709309-52710449:-.alignment
chr19:52709309-52710449:-ENST00000596702.4ENSG00000213020.7ZNF611intronicMLT1A,AluSz,AluSc,AluSpchr19:52709309-52710449:-.alignment
chr19:52709309-52710449:-ENST00000597343.5ENSG00000213020.7ZNF611intronicMLT1A,AluSz,AluSc,AluSpchr19:52709309-52710449:-.alignment
chr19:52709309-52710449:-ENST00000598639.4ENSG00000213020.7ZNF611intronicMLT1A,AluSz,AluSc,AluSpchr19:52709309-52710449:-.alignment
chr19:52709309-52710449:-ENST00000598723.4ENSG00000213020.7ZNF611intronicMLT1A,AluSz,AluSc,AluSpchr19:52709309-52710449:-.alignment
chr19:52709309-52710449:-ENST00000600943.4ENSG00000213020.7ZNF611intronicMLT1A,AluSz,AluSc,AluSpchr19:52709309-52710449:-.alignment
chr19:52709309-52710449:-ENST00000601249.4ENSG00000213020.7ZNF611intronicMLT1A,AluSz,AluSc,AluSpchr19:52709309-52710449:-.alignment
chr19:52709309-52710449:-ENST00000601643.4ENSG00000213020.7ZNF611intronicMLT1A,AluSz,AluSc,AluSpchr19:52709309-52710449:-.alignment
chr19:52709309-52710449:-ENST00000602162.4ENSG00000213020.7ZNF611intronicMLT1A,AluSz,AluSc,AluSpchr19:52709309-52710449:-.alignment
chr19:52722271-52723531:-ENST00000596776.1ENSG00000213020.7ZNF611ncRNA_exonicAluSp,AluJb,AluJo,(ATTA)nchr19:52722271-52723531:-.alignment
chr19:52726564-52728465:-ENST00000597566.4ENSG00000213020.7ZNF611ncRNA_intronicAluY,MER67C,LTR24,L1M4,AluSq2,AluSz,AluSx3,(T)nchr19:52726564-52728465:-.alignment
chr19:52726564-52728465:-ENST00000599798.1ENSG00000213020.7ZNF611ncRNA_intronicAluY,MER67C,LTR24,L1M4,AluSq2,AluSz,AluSx3,(T)nchr19:52726564-52728465:-.alignment
chr19:52726564-52728465:-ENST00000601447.4ENSG00000213020.7ZNF611ncRNA_intronicAluY,MER67C,LTR24,L1M4,AluSq2,AluSz,AluSx3,(T)nchr19:52726564-52728465:-.alignment
chr19:52732829-52733610:-ENST00000597566.4ENSG00000213020.7ZNF611ncRNA_intronic(ATTA)n,AluJr,AluJbchr19:52732829-52733610:-.alignment
chr19:52732829-52733610:-ENST00000599798.1ENSG00000213020.7ZNF611ncRNA_intronic(ATTA)n,AluJr,AluJbchr19:52732829-52733610:-.alignment
chr19:52732829-52733610:-ENST00000601447.4ENSG00000213020.7ZNF611ncRNA_intronic(ATTA)n,AluJr,AluJbchr19:52732829-52733610:-.alignment


Top

2. Tumor-specific enriched editing regions for ZNF611


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr19:52703301-52704156:-KICHEER1.3213e-05image
ENSG00000213020.7,ZNF611KICHEAG1.3213e-05image
chr19:52703301-52704156:-LUSCEER1.0453e-02image
ENSG00000213020.7,ZNF611LUSCEAG1.0963e-02image
chr19:52703301-52704156:-PRADEER7.2365e-05image
ENSG00000213020.7,ZNF611PRADEAG7.0930e-05image
chr19:52703301-52704156:-STADEER9.7696e-04image
ENSG00000213020.7,ZNF611STADEAG4.1284e-03image
chr19:52703301-52704156:-UCECEER7.8648e-04image
ENSG00000213020.7,ZNF611UCECEAG9.1209e-04image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000213020.7,ZNF611TGCTPathEAG3.5405e-031.9344e-030.3479image
chr19:52703301-52704156:-TGCTPathEER3.3386e-031.8327e-030.3496image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for ZNF611


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr19:52703301-52704156:-KIRPEERENSG00000117983,MUC5B-0.18241.8186e-021.2748e-120.4122imageNCSTF2T;DDX54;EIF4A3;FBL;HNRNPK;IGF2BP2;NOP56;NOP58;SRSF1;TAF15MUC5B
chr19:52703301-52704156:-ESCAEERENSG00000213020,ZNF611-0.48145.9104e-061.6019e-09-0.4677imageNCSTF2T;DDX54;EIF4A3;FBL;HNRNPA2B1;HNRNPK;IGF2BP2;NOP56;NOP58;PRPF8;PTBP1;RBM10;RBM22;SRSF1;TAF15;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_P53_PATHWAY
chr19:52703301-52704156:-ESCAEERENSG00000204604,ZNF468-0.41681.8346e-044.0699e-08-0.4297imageNCSTF2T;DDX54;EIF4A3;FBL;HNRNPA2B1;HNRNPK;IGF2BP2;NOP56;NOP58;PRPF8;PTBP1;RBM10;RBM22;SRSF1;SRSF7;TAF15;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_HYPOXIA
chr19:52703301-52704156:-ESCAEERENSG00000198482,ZNF808-0.40653.8651e-041.3917e-07-0.4140imageNCSTF2T;DDX54;EIF4A3;FBL;HNRNPA2B1;HNRNPK;IGF2BP2;NOP58;PRPF8;PTBP1;RBM10;RBM22;SRSF1;TAF15;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_P53_PATHWAY
chr19:52703301-52704156:-ESCAEERENSG00000198538,ZNF28-0.40744.1899e-041.7323e-07-0.4111imageNCSTF2T;DDX54;EIF4A3;FBL;HNRNPK;IGF2BP2;NOP56;NOP58;PRPF8;PTBP1;RBM10;RBM22;SRSF1;SRSF7;TAF15;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_HYPOXIA
chr19:52703301-52704156:-PCPGEERENSG00000106244,PDAP10.32947.1515e-032.9434e-070.4286imageNCSTF2T;DDX54;EIF4A3;FBL;HNRNPA2B1;HNRNPK;IGF2BP2;NOP56;NOP58;PRPF8;PTBP1;RBM10;RBM22;SRSF1;SRSF7;TAF15;U2AF2NAB_cells_memoryGSVA_HALLMARK_MYC_TARGETS_V1
chr19:52703301-52704156:-TGCTEERENSG00000124383,MPHOSPH10-0.50193.1603e-073.5261e-11-0.5194imageNCSTF2T;DDX54;EIF4A3;FBL;HNRNPA2B1;HNRNPK;IGF2BP2;NOP56;NOP58;PRPF8;PTBP1;RBM10;RBM22;SRSF1;SRSF7;TAF15;U2AF2NAMacrophages_M2GSVA_HALLMARK_APICAL_JUNCTION
chr19:52703301-52704156:-TGCTEERENSG00000170627,GTSF1-0.48569.6769e-072.9960e-08-0.4445imageNCSTF2T;HNRNPK;IGF2BP2;NOP56;PRPF8;PTBP1;RBM10;RBM22;SRSF1;TAF15;U2AF2NAMacrophages_M2GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY
chr19:52703301-52704156:-TGCTEERENSG00000104835,SARS2-0.48131.2438e-064.3176e-09-0.4679imageNCSTF2T;DDX54;EIF4A3;FBL;HNRNPA2B1;HNRNPK;IGF2BP2;NOP56;NOP58;PRPF8;PTBP1;RBM10;RBM22;SRSF1;SRSF7;TAF15;U2AF2NAMacrophages_M2GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY
chr19:52703301-52704156:-TGCTEERENSG00000240563,L1TD1-0.49501.2451e-061.7891e-08-0.4509imageNEIF4A3;IGF2BP2;SRSF1;TAF15;U2AF2NAT_cells_CD4_memory_activatedGSVA_HALLMARK_MYC_TARGETS_V2
chr19:52703301-52704156:-KIRPEERENSG00000117983,MUC5B-0.18241.8186e-021.2748e-120.4122imageNCSTF2T;DDX54;EIF4A3;FBL;HNRNPK;IGF2BP2;NOP56;NOP58;SRSF1;TAF15MUC5B
chr19:52703301-52704156:-ESCAEERENSG00000213020,ZNF611-0.48145.9104e-061.6019e-09-0.4677imageNCSTF2T;DDX54;EIF4A3;FBL;HNRNPA2B1;HNRNPK;IGF2BP2;NOP56;NOP58;PRPF8;PTBP1;RBM10;RBM22;SRSF1;TAF15;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_P53_PATHWAY
chr19:52703301-52704156:-ESCAEERENSG00000204604,ZNF468-0.41681.8346e-044.0699e-08-0.4297imageNCSTF2T;DDX54;EIF4A3;FBL;HNRNPA2B1;HNRNPK;IGF2BP2;NOP56;NOP58;PRPF8;PTBP1;RBM10;RBM22;SRSF1;SRSF7;TAF15;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_HYPOXIA
chr19:52703301-52704156:-ESCAEERENSG00000198482,ZNF808-0.40653.8651e-041.3917e-07-0.4140imageNCSTF2T;DDX54;EIF4A3;FBL;HNRNPA2B1;HNRNPK;IGF2BP2;NOP58;PRPF8;PTBP1;RBM10;RBM22;SRSF1;TAF15;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_P53_PATHWAY
chr19:52703301-52704156:-ESCAEERENSG00000198538,ZNF28-0.40744.1899e-041.7323e-07-0.4111imageNCSTF2T;DDX54;EIF4A3;FBL;HNRNPK;IGF2BP2;NOP56;NOP58;PRPF8;PTBP1;RBM10;RBM22;SRSF1;SRSF7;TAF15;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_HYPOXIA
chr19:52703301-52704156:-PCPGEERENSG00000106244,PDAP10.32947.1515e-032.9434e-070.4286imageNCSTF2T;DDX54;EIF4A3;FBL;HNRNPA2B1;HNRNPK;IGF2BP2;NOP56;NOP58;PRPF8;PTBP1;RBM10;RBM22;SRSF1;SRSF7;TAF15;U2AF2NAB_cells_memoryGSVA_HALLMARK_MYC_TARGETS_V1
chr19:52703301-52704156:-TGCTEERENSG00000124383,MPHOSPH10-0.50193.1603e-073.5261e-11-0.5194imageNCSTF2T;DDX54;EIF4A3;FBL;HNRNPA2B1;HNRNPK;IGF2BP2;NOP56;NOP58;PRPF8;PTBP1;RBM10;RBM22;SRSF1;SRSF7;TAF15;U2AF2NAMacrophages_M2GSVA_HALLMARK_APICAL_JUNCTION
chr19:52703301-52704156:-TGCTEERENSG00000170627,GTSF1-0.48569.6769e-072.9960e-08-0.4445imageNCSTF2T;HNRNPK;IGF2BP2;NOP56;PRPF8;PTBP1;RBM10;RBM22;SRSF1;TAF15;U2AF2NAMacrophages_M2GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY
chr19:52703301-52704156:-TGCTEERENSG00000104835,SARS2-0.48131.2438e-064.3176e-09-0.4679imageNCSTF2T;DDX54;EIF4A3;FBL;HNRNPA2B1;HNRNPK;IGF2BP2;NOP56;NOP58;PRPF8;PTBP1;RBM10;RBM22;SRSF1;SRSF7;TAF15;U2AF2NAMacrophages_M2GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY
chr19:52703301-52704156:-TGCTEERENSG00000240563,L1TD1-0.49501.2451e-061.7891e-08-0.4509imageNEIF4A3;IGF2BP2;SRSF1;TAF15;U2AF2NAT_cells_CD4_memory_activatedGSVA_HALLMARK_MYC_TARGETS_V2
chr19:52703301-52704156:-KIRPEERENSG00000117983,MUC5B-0.18241.8186e-021.2748e-120.4122imageNCSTF2T;DDX54;EIF4A3;FBL;HNRNPK;IGF2BP2;NOP56;NOP58;SRSF1;TAF15MUC5B
chr19:52703301-52704156:-ESCAEERENSG00000213020,ZNF611-0.48145.9104e-061.6019e-09-0.4677imageNCSTF2T;DDX54;EIF4A3;FBL;HNRNPA2B1;HNRNPK;IGF2BP2;NOP56;NOP58;PRPF8;PTBP1;RBM10;RBM22;SRSF1;TAF15;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_P53_PATHWAY
chr19:52703301-52704156:-ESCAEERENSG00000204604,ZNF468-0.41681.8346e-044.0699e-08-0.4297imageNCSTF2T;DDX54;EIF4A3;FBL;HNRNPA2B1;HNRNPK;IGF2BP2;NOP56;NOP58;PRPF8;PTBP1;RBM10;RBM22;SRSF1;SRSF7;TAF15;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_HYPOXIA
chr19:52703301-52704156:-ESCAEERENSG00000198482,ZNF808-0.40653.8651e-041.3917e-07-0.4140imageNCSTF2T;DDX54;EIF4A3;FBL;HNRNPA2B1;HNRNPK;IGF2BP2;NOP58;PRPF8;PTBP1;RBM10;RBM22;SRSF1;TAF15;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_P53_PATHWAY
chr19:52703301-52704156:-ESCAEERENSG00000198538,ZNF28-0.40744.1899e-041.7323e-07-0.4111imageNCSTF2T;DDX54;EIF4A3;FBL;HNRNPK;IGF2BP2;NOP56;NOP58;PRPF8;PTBP1;RBM10;RBM22;SRSF1;SRSF7;TAF15;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_HYPOXIA
chr19:52703301-52704156:-PCPGEERENSG00000106244,PDAP10.32947.1515e-032.9434e-070.4286imageNCSTF2T;DDX54;EIF4A3;FBL;HNRNPA2B1;HNRNPK;IGF2BP2;NOP56;NOP58;PRPF8;PTBP1;RBM10;RBM22;SRSF1;SRSF7;TAF15;U2AF2NAB_cells_memoryGSVA_HALLMARK_MYC_TARGETS_V1
chr19:52703301-52704156:-TGCTEERENSG00000124383,MPHOSPH10-0.50193.1603e-073.5261e-11-0.5194imageNCSTF2T;DDX54;EIF4A3;FBL;HNRNPA2B1;HNRNPK;IGF2BP2;NOP56;NOP58;PRPF8;PTBP1;RBM10;RBM22;SRSF1;SRSF7;TAF15;U2AF2NAMacrophages_M2GSVA_HALLMARK_APICAL_JUNCTION
chr19:52703301-52704156:-TGCTEERENSG00000170627,GTSF1-0.48569.6769e-072.9960e-08-0.4445imageNCSTF2T;HNRNPK;IGF2BP2;NOP56;PRPF8;PTBP1;RBM10;RBM22;SRSF1;TAF15;U2AF2NAMacrophages_M2GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY
chr19:52703301-52704156:-TGCTEERENSG00000104835,SARS2-0.48131.2438e-064.3176e-09-0.4679imageNCSTF2T;DDX54;EIF4A3;FBL;HNRNPA2B1;HNRNPK;IGF2BP2;NOP56;NOP58;PRPF8;PTBP1;RBM10;RBM22;SRSF1;SRSF7;TAF15;U2AF2NAMacrophages_M2GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY
chr19:52703301-52704156:-TGCTEERENSG00000240563,L1TD1-0.49501.2451e-061.7891e-08-0.4509imageNEIF4A3;IGF2BP2;SRSF1;TAF15;U2AF2NAT_cells_CD4_memory_activatedGSVA_HALLMARK_MYC_TARGETS_V2
chr19:52703301-52704156:-KIRPEERENSG00000117983,MUC5B-0.18241.8186e-021.2748e-120.4122imageNCSTF2T;DDX54;EIF4A3;FBL;HNRNPK;IGF2BP2;NOP56;NOP58;SRSF1;TAF15MUC5B
chr19:52703301-52704156:-ESCAEERENSG00000213020,ZNF611-0.48145.9104e-061.6019e-09-0.4677imageNCSTF2T;DDX54;EIF4A3;FBL;HNRNPA2B1;HNRNPK;IGF2BP2;NOP56;NOP58;PRPF8;PTBP1;RBM10;RBM22;SRSF1;TAF15;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_P53_PATHWAY
chr19:52703301-52704156:-ESCAEERENSG00000204604,ZNF468-0.41681.8346e-044.0699e-08-0.4297imageNCSTF2T;DDX54;EIF4A3;FBL;HNRNPA2B1;HNRNPK;IGF2BP2;NOP56;NOP58;PRPF8;PTBP1;RBM10;RBM22;SRSF1;SRSF7;TAF15;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_HYPOXIA
chr19:52703301-52704156:-ESCAEERENSG00000198482,ZNF808-0.40653.8651e-041.3917e-07-0.4140imageNCSTF2T;DDX54;EIF4A3;FBL;HNRNPA2B1;HNRNPK;IGF2BP2;NOP58;PRPF8;PTBP1;RBM10;RBM22;SRSF1;TAF15;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_P53_PATHWAY
chr19:52703301-52704156:-ESCAEERENSG00000198538,ZNF28-0.40744.1899e-041.7323e-07-0.4111imageNCSTF2T;DDX54;EIF4A3;FBL;HNRNPK;IGF2BP2;NOP56;NOP58;PRPF8;PTBP1;RBM10;RBM22;SRSF1;SRSF7;TAF15;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_HYPOXIA
chr19:52703301-52704156:-PCPGEERENSG00000106244,PDAP10.32947.1515e-032.9434e-070.4286imageNCSTF2T;DDX54;EIF4A3;FBL;HNRNPA2B1;HNRNPK;IGF2BP2;NOP56;NOP58;PRPF8;PTBP1;RBM10;RBM22;SRSF1;SRSF7;TAF15;U2AF2NAB_cells_memoryGSVA_HALLMARK_MYC_TARGETS_V1
chr19:52703301-52704156:-TGCTEERENSG00000124383,MPHOSPH10-0.50193.1603e-073.5261e-11-0.5194imageNCSTF2T;DDX54;EIF4A3;FBL;HNRNPA2B1;HNRNPK;IGF2BP2;NOP56;NOP58;PRPF8;PTBP1;RBM10;RBM22;SRSF1;SRSF7;TAF15;U2AF2NAMacrophages_M2GSVA_HALLMARK_APICAL_JUNCTION
chr19:52703301-52704156:-TGCTEERENSG00000170627,GTSF1-0.48569.6769e-072.9960e-08-0.4445imageNCSTF2T;HNRNPK;IGF2BP2;NOP56;PRPF8;PTBP1;RBM10;RBM22;SRSF1;TAF15;U2AF2NAMacrophages_M2GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY
chr19:52703301-52704156:-TGCTEERENSG00000104835,SARS2-0.48131.2438e-064.3176e-09-0.4679imageNCSTF2T;DDX54;EIF4A3;FBL;HNRNPA2B1;HNRNPK;IGF2BP2;NOP56;NOP58;PRPF8;PTBP1;RBM10;RBM22;SRSF1;SRSF7;TAF15;U2AF2NAMacrophages_M2GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY
chr19:52703301-52704156:-TGCTEERENSG00000240563,L1TD1-0.49501.2451e-061.7891e-08-0.4509imageNEIF4A3;IGF2BP2;SRSF1;TAF15;U2AF2NAT_cells_CD4_memory_activatedGSVA_HALLMARK_MYC_TARGETS_V2
chr19:52703301-52704156:-KIRPEERENSG00000117983,MUC5B-0.18241.8186e-021.2748e-120.4122imageNCSTF2T;DDX54;EIF4A3;FBL;HNRNPK;IGF2BP2;NOP56;NOP58;SRSF1;TAF15MUC5B
chr19:52703301-52704156:-ESCAEERENSG00000213020,ZNF611-0.48145.9104e-061.6019e-09-0.4677imageNCSTF2T;DDX54;EIF4A3;FBL;HNRNPA2B1;HNRNPK;IGF2BP2;NOP56;NOP58;PRPF8;PTBP1;RBM10;RBM22;SRSF1;TAF15;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_P53_PATHWAY
chr19:52703301-52704156:-ESCAEERENSG00000204604,ZNF468-0.41681.8346e-044.0699e-08-0.4297imageNCSTF2T;DDX54;EIF4A3;FBL;HNRNPA2B1;HNRNPK;IGF2BP2;NOP56;NOP58;PRPF8;PTBP1;RBM10;RBM22;SRSF1;SRSF7;TAF15;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_HYPOXIA
chr19:52703301-52704156:-ESCAEERENSG00000198482,ZNF808-0.40653.8651e-041.3917e-07-0.4140imageNCSTF2T;DDX54;EIF4A3;FBL;HNRNPA2B1;HNRNPK;IGF2BP2;NOP58;PRPF8;PTBP1;RBM10;RBM22;SRSF1;TAF15;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_P53_PATHWAY
chr19:52703301-52704156:-ESCAEERENSG00000198538,ZNF28-0.40744.1899e-041.7323e-07-0.4111imageNCSTF2T;DDX54;EIF4A3;FBL;HNRNPK;IGF2BP2;NOP56;NOP58;PRPF8;PTBP1;RBM10;RBM22;SRSF1;SRSF7;TAF15;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_HYPOXIA
chr19:52703301-52704156:-PCPGEERENSG00000106244,PDAP10.32947.1515e-032.9434e-070.4286imageNCSTF2T;DDX54;EIF4A3;FBL;HNRNPA2B1;HNRNPK;IGF2BP2;NOP56;NOP58;PRPF8;PTBP1;RBM10;RBM22;SRSF1;SRSF7;TAF15;U2AF2NAB_cells_memoryGSVA_HALLMARK_MYC_TARGETS_V1
chr19:52703301-52704156:-TGCTEERENSG00000124383,MPHOSPH10-0.50193.1603e-073.5261e-11-0.5194imageNCSTF2T;DDX54;EIF4A3;FBL;HNRNPA2B1;HNRNPK;IGF2BP2;NOP56;NOP58;PRPF8;PTBP1;RBM10;RBM22;SRSF1;SRSF7;TAF15;U2AF2NAMacrophages_M2GSVA_HALLMARK_APICAL_JUNCTION
chr19:52703301-52704156:-TGCTEERENSG00000170627,GTSF1-0.48569.6769e-072.9960e-08-0.4445imageNCSTF2T;HNRNPK;IGF2BP2;NOP56;PRPF8;PTBP1;RBM10;RBM22;SRSF1;TAF15;U2AF2NAMacrophages_M2GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY
chr19:52703301-52704156:-TGCTEERENSG00000104835,SARS2-0.48131.2438e-064.3176e-09-0.4679imageNCSTF2T;DDX54;EIF4A3;FBL;HNRNPA2B1;HNRNPK;IGF2BP2;NOP56;NOP58;PRPF8;PTBP1;RBM10;RBM22;SRSF1;SRSF7;TAF15;U2AF2NAMacrophages_M2GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY
chr19:52703301-52704156:-TGCTEERENSG00000240563,L1TD1-0.49501.2451e-061.7891e-08-0.4509imageNEIF4A3;IGF2BP2;SRSF1;TAF15;U2AF2NAT_cells_CD4_memory_activatedGSVA_HALLMARK_MYC_TARGETS_V2

More results



Top

4. Enriched editing regions and immune related splicing for ZNF611


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr19:52703301-52704156:-
KIRPEERIRENSG00000188938.11chr993450474:93450599:93450944:93451114-0.27014.4525e-054.7845e-10-0.4164imageNCSTF2T;DDX54;EIF4A3;FBL;HNRNPA2B1;HNRNPK;IGF2BP2;NOP56;NOP58;PRPF8;PTBP1;RBM10;RBM22;SRSF1;SRSF7;TAF15;U2AF2NAMacrophages_M1GSVA_HALLMARK_PANCREAS_BETA_CELLS
ENSG00000213020.7,ZNF611
PCPGEAGIRENSG00000171105.9chr197125282:7125527:7126583:7126651-0.37331.6124e-031.3480e-06-0.4295imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CSTF2T;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;LIN28;LIN28A;LIN28B;MOV10;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RBFOX2;RBM10;RBM47;RNF219;SF3A3;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;YTHDC1;YTHDF1;ZNF184INSRB_cells_naiveGSVA_HALLMARK_HEME_METABOLISM
chr19:52703301-52704156:-
PCPGEERA5ENSG00000116001.11chr270227734:70227822:70229058:70229091:70228343:702290910.29152.1918e-021.7792e-050.4002imageNCSTF2T;DDX54;EIF4A3;FBL;HNRNPA2B1;HNRNPK;IGF2BP2;NOP56;NOP58;PRPF8;PTBP1;RBM10;RBM22;SRSF1;SRSF7;TAF15;U2AF2TIA1NK_cells_activatedGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
ENSG00000213020.7,ZNF611
PCPGEAGA5ENSG00000116001.11chr270227734:70227822:70229058:70229091:70228343:702290910.29082.0912e-021.7883e-050.4001imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RNF219;SAFB2;SF3A3;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184TIA1NK_cells_activatedGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
ENSG00000213020.7,ZNF611
PCPGEAGIRENSG00000116001.11chr270224553:70227822:70229058:70229091-0.28233.8503e-028.7546e-06-0.4098imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RNF219;SAFB2;SF3A3;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184TIA1B_cells_naiveGSVA_HALLMARK_UV_RESPONSE_UP
chr19:52703301-52704156:-
PCPGEERIRENSG00000116001.11chr270224553:70227822:70229058:70229091-0.28373.9183e-028.6633e-06-0.4100imageNCSTF2T;DDX54;EIF4A3;FBL;HNRNPA2B1;HNRNPK;IGF2BP2;NOP56;NOP58;PRPF8;PTBP1;RBM10;RBM22;SRSF1;SRSF7;TAF15;U2AF2TIA1B_cells_naiveGSVA_HALLMARK_UV_RESPONSE_UP
chr19:52703301-52704156:-
PCPGEERIRENSG00000171105.9chr197125282:7125527:7126583:7126651-0.37431.7247e-031.3381e-06-0.4296imageNCSTF2T;DDX54;EIF4A3;FBL;HNRNPA2B1;HNRNPK;IGF2BP2;NOP56;NOP58;PRPF8;PTBP1;RBM10;SRSF1;SRSF7;TAF15;U2AF2INSRB_cells_naiveGSVA_HALLMARK_HEME_METABOLISM
ENSG00000213020.7,ZNF611
TGCTEAGESENSG00000099889.9chr2219969897:19970743:19971215:19971335:19971885:19971971-0.29683.5736e-021.0886e-07-0.4321imageNAIFM1;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;LIN28;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RBFOX2;RBM10;RBM22;SF3A3;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;VIM;YTHDC1;YTHDF1;YWHAG;ZNF184ARVCFMacrophages_M2GSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION
chr19:52703301-52704156:-
TGCTEERIRENSG00000105397.9chr1910352433:10353098:10354041:103541030.34928.8140e-033.8414e-080.4428imageNCSTF2T;DDX54;EIF4A3;FBL;HNRNPA2B1;HNRNPK;IGF2BP2;NOP56;NOP58;PRPF8;PTBP1;RBM10;RBM22;SRSF1;SRSF7;TAF15;U2AF2TYK2Macrophages_M2GSVA_HALLMARK_SPERMATOGENESIS
ENSG00000213020.7,ZNF611
TGCTEAGMEXENSG00000071564.10chr191611805:1611849:1611990:1612430:1615423:1615485:1615685:16157410.31122.2225e-024.7443e-070.4146imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RNF219;SAFB2;SF3A3;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;ZNF184TCF3Macrophages_M2GSVA_HALLMARK_APICAL_JUNCTION

More results



Top

5. Enriched editing regions and immune infiltration for ZNF611


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
ENSG00000213020.7,ZNF611ACCEAGMacrophages_M16.0558e-03-0.4818image
chr19:52703301-52704156:-BLCAEERT_cells_CD4_naive3.3340e-02-0.1281image
chr19:52703301-52704156:-BRCAEERNK_cells_resting4.3223e-030.0903image
ENSG00000213020.7,ZNF611BRCAEAGNK_cells_resting6.2921e-030.0864image
ENSG00000213020.7,ZNF611CHOLEAGT_cells_follicular_helper1.3828e-02-0.4598image
chr19:52703301-52704156:-COADEERPlasma_cells6.3836e-030.2563image
ENSG00000213020.7,ZNF611COADEAGDendritic_cells_activated1.1521e-030.3020image
ENSG00000213020.7,ZNF611DLBCEAGT_cells_gamma_delta2.6194e-050.7482image
chr19:52703301-52704156:-ESCAEERT_cells_gamma_delta6.1131e-040.2766image
ENSG00000213020.7,ZNF611ESCAEAGT_cells_gamma_delta7.5187e-040.2722image
chr19:52703301-52704156:-HNSCEERT_cells_CD4_memory_resting2.8090e-030.2179image
ENSG00000213020.7,ZNF611HNSCEAGDendritic_cells_activated2.6623e-030.2191image
chr19:52703301-52704156:-KIRCEERMacrophages_M11.6727e-02-0.1230image
ENSG00000213020.7,ZNF611KIRCEAGMacrophages_M11.6755e-02-0.1230image
chr19:52703301-52704156:-KIRPEERDendritic_cells_resting4.4043e-02-0.1220image
ENSG00000213020.7,ZNF611LAMLEAGT_cells_CD4_naive2.4774e-020.2049image
chr19:52703301-52704156:-LGGEERMacrophages_M02.7704e-02-0.1101image
ENSG00000213020.7,ZNF611LGGEAGMacrophages_M02.7423e-02-0.1103image
ENSG00000213020.7,ZNF611LIHCEAGT_cells_gamma_delta6.2925e-03-0.3191image
chr19:52703301-52704156:-LUSCEERT_cells_CD4_naive1.8647e-02-0.1327image
ENSG00000213020.7,ZNF611LUSCEAGT_cells_follicular_helper1.9782e-02-0.1313image
chr19:52703301-52704156:-MESOEERNK_cells_resting1.4169e-030.4312image
ENSG00000213020.7,ZNF611MESOEAGNK_cells_resting1.4169e-030.4312image
chr19:52703301-52704156:-OVEERT_cells_CD4_naive2.4501e-040.2227image
chr19:52726564-52728465:-OVEERMacrophages_M24.3297e-02-0.2078image
ENSG00000213020.7,ZNF611OVEAGT_cells_CD4_naive1.9230e-040.2263image
chr19:52703301-52704156:-PAADEERB_cells_memory2.6576e-030.2777image
ENSG00000213020.7,ZNF611PAADEAGB_cells_memory2.6576e-030.2777image
chr19:52703301-52704156:-PRADEERMacrophages_M23.0584e-020.1105image
ENSG00000213020.7,ZNF611PRADEAGMacrophages_M23.0169e-020.1106image
ENSG00000213020.7,ZNF611READEAGMacrophages_M01.3325e-03-0.5143image
chr19:52703301-52704156:-SARCEEREosinophils1.1620e-020.1997image
ENSG00000213020.7,ZNF611SARCEAGEosinophils1.1751e-020.1988image
chr19:52703301-52704156:-STADEERT_cells_CD82.2464e-020.1288image
chr19:52726564-52728465:-STADEERT_cells_gamma_delta1.8176e-020.2200image
ENSG00000213020.7,ZNF611STADEAGT_cells_CD83.3762e-030.1631image
chr19:52703301-52704156:-TGCTEERMacrophages_M27.2302e-050.3267image
ENSG00000213020.7,ZNF611TGCTEAGMacrophages_M26.4696e-050.3288image
chr19:52703301-52704156:-THCAEERT_cells_CD4_memory_activated1.5707e-020.1187image
ENSG00000213020.7,ZNF611THCAEAGT_cells_CD4_memory_activated1.5707e-020.1187image
chr19:52703301-52704156:-UCECEERMacrophages_M03.3454e-020.1968image
ENSG00000213020.7,ZNF611UCECEAGMacrophages_M03.4373e-020.1958image
chr19:52703301-52704156:-UCSEERPlasma_cells3.1692e-02-0.3446image
ENSG00000213020.7,ZNF611UCSEAGPlasma_cells3.0672e-02-0.3466image
ENSG00000213020.7,ZNF611UVMEAGDendritic_cells_activated7.8243e-030.5293image


Top

6. Enriched editing regions and immune gene sets for ZNF611


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr19:52703301-52704156:-BLCAGSVA_HALLMARK_HYPOXIAEER1.3639e-020.1483image
ENSG00000213020.7,ZNF611BLCAGSVA_HALLMARK_APICAL_JUNCTIONEAG1.7351e-020.1426image
chr19:52703301-52704156:-BRCAGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER8.2843e-060.1406image
ENSG00000213020.7,ZNF611BRCAGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG8.7210e-060.1402image
ENSG00000213020.7,ZNF611CESCGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG2.3873e-020.1684image
ENSG00000213020.7,ZNF611CHOLGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEAG1.5376e-03-0.5701image
chr19:52703301-52704156:-COADGSVA_HALLMARK_HEME_METABOLISMEER1.8651e-03-0.2908image
ENSG00000213020.7,ZNF611COADGSVA_HALLMARK_HEME_METABOLISMEAG2.1095e-03-0.2863image
ENSG00000213020.7,ZNF611DLBCGSVA_HALLMARK_MITOTIC_SPINDLEEAG5.7688e-05-0.7268image
chr19:52703301-52704156:-ESCAGSVA_HALLMARK_HYPOXIAEER1.4570e-030.2576image
chr19:52722271-52723531:-ESCAGSVA_HALLMARK_GLYCOLYSISEER6.0781e-030.3319image
chr19:52726564-52728465:-ESCAGSVA_HALLMARK_MYC_TARGETS_V2EER3.9780e-02-0.2708image
ENSG00000213020.7,ZNF611ESCAGSVA_HALLMARK_HYPOXIAEAG4.7899e-030.2292image
chr19:52703301-52704156:-GBMGSVA_HALLMARK_FATTY_ACID_METABOLISMEER2.4601e-030.2540image
ENSG00000213020.7,ZNF611GBMGSVA_HALLMARK_FATTY_ACID_METABOLISMEAG2.4090e-030.2545image
chr19:52703301-52704156:-HNSCGSVA_HALLMARK_BILE_ACID_METABOLISMEER6.1403e-040.2489image
ENSG00000213020.7,ZNF611HNSCGSVA_HALLMARK_BILE_ACID_METABOLISMEAG6.1730e-040.2488image
ENSG00000213020.7,ZNF611KICHGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG1.3900e-02-0.3187image
chr19:52703301-52704156:-KICHGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER1.3900e-02-0.3187image
ENSG00000213020.7,ZNF611KIRCGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG3.2746e-030.1509image
chr19:52703301-52704156:-KIRCGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER3.9078e-040.1815image
ENSG00000213020.7,ZNF611KIRPGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG1.5110e-030.1911image
chr19:52703301-52704156:-KIRPGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER9.3359e-040.1992image
ENSG00000213020.7,ZNF611LGGGSVA_HALLMARK_SPERMATOGENESISEAG8.2604e-04-0.1665image
chr19:52703301-52704156:-LGGGSVA_HALLMARK_SPERMATOGENESISEER8.3489e-04-0.1664image
ENSG00000213020.7,ZNF611LIHCGSVA_HALLMARK_HEME_METABOLISMEAG1.9496e-030.3591image
chr19:52703301-52704156:-LUADGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER5.7922e-040.1873image
ENSG00000213020.7,ZNF611LUADGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG5.9952e-040.1868image
chr19:52703301-52704156:-LUSCGSVA_HALLMARK_P53_PATHWAYEER4.8469e-050.2272image
ENSG00000213020.7,ZNF611LUSCGSVA_HALLMARK_P53_PATHWAYEAG5.1233e-050.2261image
chr19:52703301-52704156:-MESOGSVA_HALLMARK_APICAL_JUNCTIONEER1.9399e-02-0.3233image
ENSG00000213020.7,ZNF611MESOGSVA_HALLMARK_APICAL_JUNCTIONEAG1.9399e-02-0.3233image
ENSG00000213020.7,ZNF611OVGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.4775e-02-0.1491image
chr19:52722271-52723531:-OVGSVA_HALLMARK_PROTEIN_SECRETIONEER1.9983e-020.2903image
chr19:52703301-52704156:-OVGSVA_HALLMARK_DNA_REPAIREER1.5401e-020.1482image
chr19:52703301-52704156:-PAADGSVA_HALLMARK_FATTY_ACID_METABOLISMEER1.1056e-020.2362image
ENSG00000213020.7,ZNF611PAADGSVA_HALLMARK_FATTY_ACID_METABOLISMEAG1.1056e-020.2362image
ENSG00000213020.7,ZNF611PCPGGSVA_HALLMARK_GLYCOLYSISEAG2.6645e-030.2594image
chr19:52703301-52704156:-PCPGGSVA_HALLMARK_GLYCOLYSISEER2.6625e-030.2595image
chr19:52703301-52704156:-PRADGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER1.2060e-030.1648image
ENSG00000213020.7,ZNF611PRADGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG1.1404e-030.1654image
chr19:52703301-52704156:-SKCMGSVA_HALLMARK_UV_RESPONSE_UPEER6.8956e-030.1597image
ENSG00000213020.7,ZNF611SKCMGSVA_HALLMARK_UV_RESPONSE_UPEAG1.0720e-020.1510image
chr19:52726564-52728465:-STADGSVA_HALLMARK_E2F_TARGETSEER4.8183e-030.2611image
chr19:52703301-52704156:-STADGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER2.4082e-050.2359image
ENSG00000213020.7,ZNF611STADGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG7.5878e-050.2190image
chr19:52722271-52723531:-STADGSVA_HALLMARK_HEME_METABOLISMEER4.6605e-030.2703image
ENSG00000213020.7,ZNF611TGCTGSVA_HALLMARK_APICAL_JUNCTIONEAG4.9920e-090.4662image
chr19:52703301-52704156:-TGCTGSVA_HALLMARK_APICAL_JUNCTIONEER4.8031e-090.4667image
ENSG00000213020.7,ZNF611THCAGSVA_HALLMARK_MTORC1_SIGNALINGEAG1.6399e-020.1179image
chr19:52703301-52704156:-THCAGSVA_HALLMARK_MTORC1_SIGNALINGEER1.6399e-020.1179image
chr19:52703301-52704156:-THYMGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER1.6446e-020.2781image
ENSG00000213020.7,ZNF611THYMGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG1.6446e-020.2781image
ENSG00000213020.7,ZNF611UCECGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG3.6355e-03-0.2668image
chr19:52703301-52704156:-UCECGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER3.8754e-03-0.2651image


Top

7. Enriched editing regions and drugs for ZNF611


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000213020.7,ZNF611ACCGemcitabineEAG9.7136e-040.5632image
chr19:52703301-52704156:-BLCAKU.55933EER8.1439e-05-0.2349image
ENSG00000213020.7,ZNF611BLCACyclopamineEAG9.1285e-05-0.2325image
chr19:52703301-52704156:-BRCAAZD6244EER6.3149e-04-0.1080image
ENSG00000213020.7,ZNF611BRCAAZD6244EAG6.2512e-04-0.1080image
ENSG00000213020.7,ZNF611CESCCyclopamineEAG7.2376e-03-0.2001image
ENSG00000213020.7,ZNF611CHOLBIRB.0796EAG8.9872e-04-0.5923image
ENSG00000213020.7,ZNF611COADAZ628EAG3.6749e-040.3294image
chr19:52703301-52704156:-COADAZ628EER2.0176e-050.3910image
ENSG00000213020.7,ZNF611DLBCGNF.2EAG1.6055e-05-0.7606image
ENSG00000213020.7,ZNF611ESCABexaroteneEAG3.3975e-04-0.2887image
chr19:52726564-52728465:-ESCABleomycinEER2.2780e-02-0.2986image
chr19:52722271-52723531:-ESCACHIR.99021EER7.5929e-03-0.3234image
chr19:52703301-52704156:-ESCABexaroteneEER3.7613e-05-0.3298image
chr19:52703301-52704156:-GBMLenalidomideEER4.6913e-030.2377image
ENSG00000213020.7,ZNF611GBMLenalidomideEAG4.5044e-030.2387image
ENSG00000213020.7,ZNF611HNSCAMG.706EAG2.1757e-020.1682image
chr19:52703301-52704156:-HNSCAMG.706EER2.0188e-020.1702image
chr19:52703301-52704156:-KICHLFM.A13EER2.1187e-02-0.2995image
ENSG00000213020.7,ZNF611KICHLFM.A13EAG2.1187e-02-0.2995image
chr19:52703301-52704156:-KIRCAG.014699EER5.9728e-070.2534image
ENSG00000213020.7,ZNF611KIRCAG.014699EAG3.2684e-060.2367image
ENSG00000213020.7,ZNF611KIRPIPA.3EAG1.5524e-030.1906image
chr19:52703301-52704156:-KIRPIPA.3EER7.0888e-040.2037image
ENSG00000213020.7,ZNF611LGGJNK.Inhibitor.VIIIEAG2.5136e-030.1507image
chr19:52703301-52704156:-LGGJNK.Inhibitor.VIIIEER2.6511e-030.1499image
ENSG00000213020.7,ZNF611LIHCGSK269962AEAG7.2743e-03-0.3138image
chr19:52703301-52704156:-LUADAZD8055EER1.7898e-02-0.1295image
ENSG00000213020.7,ZNF611LUADAZD8055EAG1.4263e-02-0.1340image
chr19:52703301-52704156:-LUSCCI.1040EER1.5468e-04-0.2119image
ENSG00000213020.7,ZNF611LUSCCI.1040EAG1.5041e-04-0.2120image
ENSG00000213020.7,ZNF611MESOAZD.2281EAG1.2823e-020.3429image
chr19:52703301-52704156:-MESOAZD.2281EER1.2823e-020.3429image
chr19:52722271-52723531:-OVMethotrexateEER1.1249e-020.3150image
chr19:52732829-52733610:-OVErlotinibEER1.7537e-02-0.4049image
ENSG00000213020.7,ZNF611OVAZD6244EAG4.4078e-03-0.1737image
chr19:52726564-52728465:-OVCamptothecinEER5.5793e-030.2823image
chr19:52703301-52704156:-OVAZD6244EER2.8282e-03-0.1821image
chr19:52703301-52704156:-PAADCCT007093EER1.5243e-020.2258image
ENSG00000213020.7,ZNF611PAADCCT007093EAG1.5243e-020.2258image
ENSG00000213020.7,ZNF611PCPGIPA.3EAG3.8714e-030.2498image
chr19:52703301-52704156:-PCPGIPA.3EER3.8795e-030.2497image
ENSG00000213020.7,ZNF611PRADBMS.509744EAG1.4102e-04-0.1930image
chr19:52703301-52704156:-PRADBMS.509744EER1.4562e-04-0.1929image
ENSG00000213020.7,ZNF611READJNJ.26854165EAG4.1450e-020.3416image
ENSG00000213020.7,ZNF611SARCAZD7762EAG3.9098e-04-0.2770image
chr19:52703301-52704156:-SARCAZD7762EER2.0669e-04-0.2902image
ENSG00000213020.7,ZNF611SKCMAZD6244EAG3.2187e-02-0.1269image
chr19:52703301-52704156:-SKCMAZD6244EER3.9185e-02-0.1222image
chr19:52726564-52728465:-STADAP.24534EER1.0096e-020.2390image
chr19:52703301-52704156:-STADAZ628EER7.0288e-06-0.2505image
chr19:52722271-52723531:-STADGemcitabineEER2.0805e-020.2222image
ENSG00000213020.7,ZNF611STADAZD6244EAG1.4854e-05-0.2391image
chr19:52703301-52704156:-TGCTBI.D1870EER1.5570e-100.5044image
ENSG00000213020.7,ZNF611TGCTBI.D1870EAG1.4154e-100.5054image
ENSG00000213020.7,ZNF611THCABMS.708163EAG1.0735e-03-0.1602image
chr19:52703301-52704156:-THCABMS.708163EER1.0735e-03-0.1602image
ENSG00000213020.7,ZNF611THYMBMS.536924EAG1.2576e-02-0.2888image
chr19:52703301-52704156:-THYMBMS.536924EER1.2576e-02-0.2888image
chr19:52703301-52704156:-UCECCI.1040EER3.2466e-03-0.2699image
ENSG00000213020.7,ZNF611UCECCI.1040EAG3.3205e-03-0.2693image
ENSG00000213020.7,ZNF611UCSBX.795EAG8.8638e-030.4136image
chr19:52703301-52704156:-UCSBX.795EER8.9826e-030.4130image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType